Flare Capital Partners led the Series A round. Craft, Obvious Ventures, Eniac Ventures, InHealth Ventures, Epsilon Health ...

Rep. Frank Pallone, Jr., is seeking information from six IDR entities amid concerns about No Surprises Act arbitration ...

Forus' $150 million Series C round was led by Bain Capital Ventures, with participation from Thrive Capital, General Catalyst ...

Nutromics earned FDA breakthrough device designation for its wearable patch that tracks vancomycin levels in real time. The ...

In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — ...

A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the ...

GSK’s messenger RNA vaccine for seasonal influenza is designed to prompt an immune response to two proteins on the surface of ...

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic ...

Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while ...

A PHTI analysis found that virtual CKD management programs have little impact on disease progression or healthcare spending ...

The 2026 Healthcare AI Readiness Index, a new report by Cotiviti and MedCity News, is based on a survey of 70 healthcare leaders over the summer and shares candid views of how they balance harnessing ...

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, ...